Ind Swift Laboratories Ltd vs Krebs Biochemicals Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 162.9 as of 12 Jun 15:30 . The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 yearsThe P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 yearsThe Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ind-Swift Laboratories Ltd for the Mar '26 is ₹ 172.01 crore as compare to the Dec '25 revenue of ₹ 178.43 crore. This represent the decline of -3.6% The revenue of Krebs Biochemicals & Industries Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Laboratories Ltd for the Mar '26 is ₹ 17.64 crore as compare to the Dec '25 ebitda of ₹ 25.9 crore. This represent the decline of -31.89% The ebitda of Krebs Biochemicals & Industries Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 15.11 crore over 8 quarters. This represents a CAGR of 286.79% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991.
The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003.
Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA.

FAQs for the comparison of Ind-Swift Laboratories Ltd and Krebs Biochemicals & Industries Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Krebs Biochemicals & Industries Ltd?

Market cap of Ind-Swift Laboratories Ltd is 1,416 Cr while Market cap of Krebs Biochemicals & Industries Ltd is 138 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Krebs Biochemicals & Industries Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Krebs Biochemicals & Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Krebs Biochemicals & Industries Ltd?

As of June 14, 2026, the Ind-Swift Laboratories Ltd stock price is INR ₹162.9. On the other hand, Krebs Biochemicals & Industries Ltd stock price is INR ₹64.06.

How do dividend payouts of Ind-Swift Laboratories Ltd and Krebs Biochemicals & Industries Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Krebs Biochemicals & Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.